The American Society of Ophthalmic Plastic & Reconstructive Surgery (ASOPRS) will be meeting in person in New Orleans to go over the latest scientific advances, said Robert G. Fante, MD, FACS, president of ASOPRS and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.
The American Society of Ophthalmic Plastic & Reconstructive Surgery (ASOPRS) will be meeting in person in New Orleans to go over the latest scientific advances, said Robert G. Fante, MD, FACS, president of ASOPRS and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.
Transcript
What are you looking forward to at the ASOPRS 2021 Fall Scientific Symposium?
We're very excited to get back together. Of course, it's been several years since we've had an opportunity to be all in the same place and New Orleans has always treated us well. So, it'll be great to hear the scientific advances that our members have put together over the last year.
And also, we have some wonderful invited speakers Dr. Kris Moe, Dr. Neal Bernard, Dr. Francesco Bernadini. And it should be really, really great.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More